KR20240006026A - 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 - Google Patents
주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 Download PDFInfo
- Publication number
- KR20240006026A KR20240006026A KR1020237040558A KR20237040558A KR20240006026A KR 20240006026 A KR20240006026 A KR 20240006026A KR 1020237040558 A KR1020237040558 A KR 1020237040558A KR 20237040558 A KR20237040558 A KR 20237040558A KR 20240006026 A KR20240006026 A KR 20240006026A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- anxiety
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181743P | 2021-04-29 | 2021-04-29 | |
| US63/181,743 | 2021-04-29 | ||
| US202163197025P | 2021-06-04 | 2021-06-04 | |
| US63/197,025 | 2021-06-04 | ||
| US202163210810P | 2021-06-15 | 2021-06-15 | |
| US63/210,810 | 2021-06-15 | ||
| US202163239096P | 2021-08-31 | 2021-08-31 | |
| US63/239,096 | 2021-08-31 | ||
| US202163285812P | 2021-12-03 | 2021-12-03 | |
| US63/285,812 | 2021-12-03 | ||
| US202163289506P | 2021-12-14 | 2021-12-14 | |
| US202163289520P | 2021-12-14 | 2021-12-14 | |
| US63/289,506 | 2021-12-14 | ||
| US63/289,520 | 2021-12-14 | ||
| US202263298601P | 2022-01-11 | 2022-01-11 | |
| US63/298,601 | 2022-01-11 | ||
| PCT/US2022/026920 WO2022232504A1 (en) | 2021-04-29 | 2022-04-29 | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240006026A true KR20240006026A (ko) | 2024-01-12 |
Family
ID=81748925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237040558A Pending KR20240006026A (ko) | 2021-04-29 | 2022-04-29 | 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240216395A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4768044A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024515829A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240006026A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022266680A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023022264A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3218072A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307991A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012727A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202308654A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022232504A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| WO2019241442A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| JP2022514510A (ja) * | 2018-12-14 | 2022-02-14 | プラクシス プレシジョン メディスンズ,インコーポレイテッド | うつ病の治療方法 |
| CA3187178A1 (en) | 2020-07-20 | 2022-01-27 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| JP2025508406A (ja) * | 2022-02-16 | 2025-03-26 | セージ セラピューティクス, インコーポレイテッド | Cns関連障害を処置するための神経活性ステロイド |
-
2022
- 2022-04-29 MX MX2023012727A patent/MX2023012727A/es unknown
- 2022-04-29 WO PCT/US2022/026920 patent/WO2022232504A1/en not_active Ceased
- 2022-04-29 IL IL307991A patent/IL307991A/en unknown
- 2022-04-29 BR BR112023022264A patent/BR112023022264A2/pt unknown
- 2022-04-29 EP EP26162693.1A patent/EP4768044A2/en active Pending
- 2022-04-29 JP JP2023566514A patent/JP2024515829A/ja active Pending
- 2022-04-29 AU AU2022266680A patent/AU2022266680A1/en active Pending
- 2022-04-29 EP EP22724335.9A patent/EP4329770A1/en not_active Ceased
- 2022-04-29 CA CA3218072A patent/CA3218072A1/en active Pending
- 2022-04-29 US US18/557,691 patent/US20240216395A1/en active Pending
- 2022-04-29 KR KR1020237040558A patent/KR20240006026A/ko active Pending
- 2022-04-29 TW TW111116469A patent/TW202308654A/zh unknown
-
2025
- 2025-04-28 JP JP2025074660A patent/JP2025111701A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4329770A1 (en) | 2024-03-06 |
| CA3218072A1 (en) | 2022-11-03 |
| US20240216395A1 (en) | 2024-07-04 |
| WO2022232504A1 (en) | 2022-11-03 |
| JP2024515829A (ja) | 2024-04-10 |
| JP2025111701A (ja) | 2025-07-30 |
| TW202308654A (zh) | 2023-03-01 |
| MX2023012727A (es) | 2023-11-08 |
| IL307991A (en) | 2023-12-01 |
| EP4768044A2 (en) | 2026-07-01 |
| AU2022266680A1 (en) | 2023-11-02 |
| BR112023022264A2 (pt) | 2024-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250339447A1 (en) | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| US20240216395A1 (en) | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression | |
| KR20240148425A (ko) | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 | |
| US20230018765A1 (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| CN113825510A (zh) | 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法 | |
| TW202539683A (zh) | 透過投予(r)-2[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑並[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧雜環丁烷-3-基)哌𠯤-1-基]戊-2-烯腈治療中度至重度氣喘 | |
| CN117580581A (zh) | 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇 | |
| RU2851101C2 (ru) | 19-nor с3,3-замещенный с21-n-пиразолилстероид и способы его применения | |
| EP4673123A1 (en) | Method for treating l-dopa-induced dyskinesia using befiradol | |
| WO2023159035A1 (en) | Neuroactive steroids for treatment of cns-related disorders | |
| HK40060751A (en) | Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |